share_log

Credit Suisse Maintains Outperform on Mineralys Therapeutics, Lowers Price Target to $37

Benzinga ·  Aug 8, 2023 08:16

Credit Suisse analyst Richard Law maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Outperform and lowers the price target from $38 to $37.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment